Table 4

Overview of prior stereotactic radiosurgery results for the reirradiation of recurrent head and neck carcinoma.

Study

Patients (#)

SRS median total dose/fx

Follow-up median, range (months)

Tumor size median, range (cc)

Prior irradiation Dose, median, range (Gy)

Toxicity

Complete Response Rate

Overall survival


Voynov et al. [13]

22

24/1-8

19, 11-40*

19.1, 2.5-140.3

97.8, 70.1-190.3 (BED10)

No Grade 4+

-

22% at 2-yrs


Heron et al. [15]

25

25-44/5

NS

44.8, 4.2-217

66-69.2

No Grade 3+

8.6%

18% at 1-yr


Roh et al. [14]

36

30/3-5

17.3

22.6, 0.2-114.9

70.2, 39.6-134.4

No Grade 4+ 36% Grade 3

42.9%

52.1% at 1-yr, 30.9% at 2-yrs


Rwigema et al. [23]

85

35/1-5

6, 1.3-39

25.1, 2.5-162

70, 32-170.7

No Grade 4+ 4.7% Grade 3

34%

48% at 1-yr, 16% at 2-yrs


Sulman et al. [31]

78§

IMRT 60 Gy

25, 0-81

64.1, 2.9-425.4

60, 16-75

20% severe Including 1% Grade 5

-

58% at 2-yrs


Siddiqui et al. [25]

44§

13-18/1 or 36-48/5-8

6.8, 1.5-48

15.5, 1.7-155‡

63.5, 50.4-74‡

6.7% Grade 3‡ 9% Grade 4‡

31%

38.1% at 1-yr 14.3% at 2-yrs


Unger et al. [24]

65

30/2-5

16*

75, 7-276

67, 32-120

11% Grade 4+

54%

41% at 2-yrs


Current Study

22 (14 N-, 8 N+)

33.7/2-5

24, 4-39

24.5, 3.4-74.4

40-65

No Grade 4+ 22.7% Grade 3

45.4% (N- 64.3%, N+ 12.5%)

N- 78.6% at 2-yrs N+ 12.5% at 2-yrs


* Surviving patients

† Additional non-recurrent patients treated, data presented for recurrent patients only unless otherwise noted.

‡ Includes non-recurrent patients.

§ Includes patients with non-squamous cell carcinomas; data presented is for combined population.

Kawaguchi et al. Radiation Oncology 2010 5:51   doi:10.1186/1748-717X-5-51

Open Data